Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2648)	11/19/2009 4:13:07 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

NBS is up > 12% on volume > 2x its ADV, after it issued a letter to its stockholders, concerning its China acquisition and the company's 'business plans'.<g> finance.yahoo.com But the stock has not been able to trade above the resistance at the $1.75 level.<g> bigcharts.marketwatch.com It has to close above that level before it can think of testing the more important resistance from the $2 level up to its June H at $2.72 If it is able to do that it could get to test the $4 level <g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2648)	3/23/2010 1:09:31 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

VVUS was up 9.51% at its intraday H, and is still up 7.63% at present. Volume is almost 1.5X its ADV The stock has closed its Sep9 UG and its nearest resistance is the March8 H at $9.80 before it can test the $10 level and the Jan11 H at $10.93. The Sept 10 H, the day after the UG was $12.88 <g> bigcharts.marketwatch.com VVUS lead product in its pipeline Qnexa, has completed PIIIs for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. Qnexa is also in a PII for treatment of type 2 diabetes and obstructive sleep apnea. VVUS has a PIII going on avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction, and a PII onf Luramist for treatment of hypoactive sexual desire disorder in women. Its MUSE (alprostadil), for ED, is already on the market. VVUS is scheduled to present at at the Barclays Capital 2010 Global Healthcare Conference in Miami Beach tomorrow afternoon, but I don't plan to drive down to attend.<g>. VVUS has reported lower revenues in the last 4Qs and losses have also been higher in the last 3Qs. The EL for 2010 is around $0.80 vs. $0.75 last Yr. and for 2011 the EL is around $0.20 <g> I still have fond memories of VVUS from the late 90s, when the main drug in its pipeline was competing with PFE's Viagra.<g> bigcharts.marketwatch.com Bernard